The Cochlear Ltd (ASX:COH) share price has been on a downward trajectory since the beginning of 2025, leaving investors wondering if it's time to add this healthcare stock to their watchlist. In my opinion, the answer is a resounding yes, but not for the reasons you might expect. While the company's performance has been somewhat underwhelming, I believe there are several compelling factors that make healthcare shares, particularly those in the medical device sector, an attractive investment opportunity. Let's delve into why, and why the current dip in COH's share price could be a strategic buying opportunity.
The Appeal of Healthcare Shares
Healthcare is an essential sector, and its importance is only set to grow. As a global leader in hearing technology, Cochlear is well-positioned to benefit from the increasing demand for medical devices. One of the key advantages of healthcare shares is their 'sticky' revenue streams. Unlike cyclical businesses that are susceptible to economic downturns, healthcare spending is often essential and less likely to be cut during tough times. This stability is particularly appealing in an uncertain economic climate.
Furthermore, the global healthcare market is projected to experience significant growth. The US, in particular, is a major driver of this growth, with healthcare spending expected to reach an impressive US$819 billion by 2027. Within this sector, sub-sectors like healthcare IT, data solutions, and software-as-a-service (SaaS) companies are forecast to grow at an even faster rate, making them highly attractive to investors seeking growth potential.
Ethical Investing and the Healthcare Sector
Another factor that makes healthcare shares appealing is the growing trend of ethical investing. A recent Morgan Stanley survey revealed that investors are increasingly interested in sustainable and ethical investments. Healthcare, as a sector that provides essential public services, is well-positioned to attract this new wave of capital. This shift in investor sentiment could significantly impact the healthcare sector, making it an attractive choice for those seeking to align their investments with their values.
COH Share Price: A Strategic Buying Opportunity
Now, let's turn our attention to the COH share price. While it's true that the stock has been on a downward trend, I believe this presents a strategic buying opportunity. One way to gauge the value of a growth company like Cochlear is to compare its price-to-sales multiple over time. Currently, COH's price-sales ratio is 3.50x, which is significantly lower than its 5-year average of 9.18x. This suggests that the share price has fallen, or sales have increased, indicating a potential undervaluation.
However, it's important to remember that investment decisions should not be based on a single metric. The Rask websites offer free online investing courses and resources, including discounted cash flow (DCF) and dividend discount models (DDM), which can provide a more comprehensive valuation of the COH share price. These models take into account the company's future cash flows and dividend payments, offering a more nuanced understanding of its value.
In conclusion, while the COH share price may have been on a downward trend, I believe it presents a strategic buying opportunity for investors. The healthcare sector's essential nature, combined with its growth potential and ethical investing appeal, makes it an attractive choice. Additionally, the current dip in the share price could be an indication of an undervaluation, making it a compelling investment proposition. As always, investors should conduct thorough research and consider their risk tolerance before making any investment decisions.
